0000000000338413

AUTHOR

Stefania Salmaso

showing 9 related works from this author

Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertussis Vaccines in Childr…

2001

Objectives.To determine the reactogenicity and immunogenicity of a fourth dose of 2 three-component acellular pertussis vaccines combined with diphtheria-tetanus-acellular pertussis (DTaP) when administered at preschool age to children primed in infancy with 3 doses of the same DTaP and who had received a diphtheria-tetanus (DT) dose at the age of 12 months.Setting.Local health units of 4 Italian regions.Study Design.Three thousand five hundred twenty-two children, who had been randomized in the first year of life to be immunized with a DTaP vaccine by either SmithKline Beecham or Chiron Biocine, were offered a booster of the same vaccine or, if refusing, a DT vaccine at the age of 5 to 6 y…

MaleDiphtheria-Tetanus VaccinePediatricsmedicine.medical_specialtyImmunization SecondaryBooster doseInjectionsmedicineHumansProspective StudiesChildAdverse effectDiphtheria-Tetanus-Pertussis VaccineDiphtheria-Tetanus-acellular Pertussis VaccinesBooster (rocketry)Reactogenicitybusiness.industryImmunogenicityItalyChild PreschoolPediatrics Perinatology and Child HealthPertussis vaccineFemalePertactinbusinessmedicine.drugPediatrics
researchProduct

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1996

Background Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin ina…

business.industryDiphtheriaFilamentous haemagglutinin adhesinGeneral Medicinemedicine.diseasePertussis toxincomplex mixturesVirologyVaccinationImmunologymedicineDiphtheria-Tetanus VaccinePertactinbusinessDiphtheria-Tetanus-acellular Pertussis VaccinesWhooping coughNew England Journal of Medicine
researchProduct

Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines

2009

OBJECTIVE. Thimerosal, a mercury compound used as a preservative in vaccines administered during infancy, has been suspected to affect neuropsychological development. We compared the neuropsychological performance, 10 years after vaccination, of 2 groups of children exposed randomly to different amounts of thimerosal through immunization. METHODS. Children who were enrolled in an efficacy trial of pertussis vaccines in 1992–1993 were contacted in 2003. Two groups of children were identified, according to thimerosal content in vaccines assigned randomly in the first year of life (cumulative ethylmercury intake of 62.5 or 137.5 μg), and were compared with respect to neuropsychological outcome…

MalePediatricsmedicine.medical_specialtyTime FactorsEthylmercury compoundTime FactorDevelopmental DisabilitiesDevelopmental DisabilitieControlled trialRandomizedNeuropsychological Testslaw.inventionchemistry.chemical_compoundEthylmercurySettore MED/38 - Pediatria Generale E SpecialisticaRandomized controlled triallawHumansMedicineNeuropsychological assessmentChildVaccinesmedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryThimerosalPreservatives PharmaceuticalInfantThimerosalNeuropsychological testExecutive functionsBoston Naming TestchemistryPediatrics Perinatology and Child HealthImmunizationFemaleNeuropsychological TestThiomersalbusinessVaccineHuman
researchProduct

How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy.

2005

Abstract The epidemiology of pertussis in Italy is described by using data from the statutory notification system and from seroepidemiology studies. Starting from the 1990s, the incidence of pertussis in Italy has shown a sharp decline and is now at the lowest level ever reached. During this time period vaccination coverage has increased from 88% in 1998 to 95% in 2003. In 1996–97, the prevalence of subjects with levels of IgG antibodies against PT greater than 2 EU/ml was 77.6%. The increase in vaccination coverage will probably change the pattern of disease transmission and increase the number of susceptible adults, unless administration of booster doses to adolescents and adults is consi…

AdultMalemedicine.medical_specialtyPediatricsAdolescentWhooping CoughImmunization SecondaryMandatory ProgramsMass VaccinationPertussiSeroepidemiologic StudiesEpidemiologyMedicineHumansPertussis vaccinationRegistriesChildWhooping coughSeroepidemiologyVaccination coveragePertussis VaccineBooster (rocketry)General VeterinaryGeneral Immunology and Microbiologybusiness.industryIncidence (epidemiology)Public Health Environmental and Occupational HealthAge FactorsInfantmedicine.diseaseAntibodies BacterialInfectious DiseasesItalyVaccination coverageChild PreschoolPopulation SurveillanceImmunologyMolecular MedicineFemalebusinessTos ferinaDisease transmissionVaccine
researchProduct

B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination

2006

MalePediatricsmedicine.medical_specialtyddc:618General VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccination/adverse effectsddc:616.07Diphtheria-Tetanus-acellular Pertussis Vaccines/adverse effectsVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesSudden Infant Death/blood/epidemiologyVaccines Combined/adverse effectsmedicineHumansMolecular MedicineFemaleHepatitis B VaccinesbusinessDiphtheria-Tetanus-Pertussis VaccineSudden infant deathVaccine
researchProduct

Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough

2003

The study of antigen specific IgG subclass distribution during disease, or during any other natural or artificial immunisation, can provide useful information on the kind of the immune response and the expected levels of protection. This is particularly true for diseases, such as pertussis in which the mechanisms underlying specific defence are still not completely understood. An investigation was therefore performed to evaluate the IgG subclass response to pertussis toxin (PT) in sera from 89 healthy vaccinated children and 131 vaccinated or unvaccinated children convalescent after a confirmed B. pertussis symptomatic infection. Antibody titres were expressed in arbitrary ELISA units/ml, a…

Bordetella pertussisWhooping CoughEnzyme-Linked Immunosorbent AssayPertussis toxinBordetella pertussisSubclassImmune systemReference ValuesmedicineHumansChildWhooping coughPertussis VaccineGeneral VeterinaryGeneral Immunology and MicrobiologybiologyPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationAntibodies BacterialVirologyVaccinationInfectious DiseasesPertussis ToxinImmunoglobulin GHumoral immunityImmunologybiology.proteinMolecular MedicineAntibodyVaccine
researchProduct

Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

1999

Abstract The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21–40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14–15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children >1 year of age, catch-up vaccination campaigns could be consider…

MaleBordetella pertussisPediatricsmedicine.medical_specialtyAgingDose-Response Relationship ImmunologicBordetella pertussisMedicineHumansAdverse effectWhooping coughImmunization SchedulePertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantbiology.organism_classificationmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationEl NiñoChild PreschoolImmunoglobulin GToxicityImmunologyMolecular MedicineFemalebusiness
researchProduct

Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines

1998

Abstract A large, randomized, placebo-controlled clinical trial in Italy on two three-component pertussis vaccines, given as DTaP in infancy, one manufactured by SmithKline and Beecham (SB) and one by Chiron Biocine (CB), found each vaccine to be 84% efficacious through the average age of 24 months. The cohort of children envolled in the trial was followed with unmodified case ascertainment procedures for nine additional calendar months, during which partial unblinding occurred, for the unvaccinated randomized group. For the DTaP groups, the specific vaccine assignment remained double-blinded throughout the entire additional observation period. Pertussis was defined as paroxysmal cough last…

Bordetella pertussisPediatricsmedicine.medical_specialtyGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryPublic Health Environmental and Occupational Healthbiology.organism_classificationmedicine.diseaseVaccine efficacySerologyClinical trialInfectious DiseasesImmunizationRelative riskCohortMolecular MedicineMedicinebusinessWhooping coughVaccine
researchProduct

Effect of duration of breastfeeding on neuropsychological development at 10 to 12years of age in a cohort of healthy children

2012

Aim The aim of this article was to explore the effect of duration of breastfeeding on neurocognitive development. Method The long-term effect of breastfeeding on neurodevelopment was examined through a battery of neuropsychological tests in 1403 children (693 females, 710 males; mean age 11y 9mo [SD 6mo], range: 10y 3mo-12y 8mo) who were originally recruited at 6 to 12weeks of age for a clinical trial on acellular pertussis vaccines. An estimated IQ was obtained from scores of the vocabulary, similarities, block design, and coding tests. Breastfeeding data had been prospectively collected throughout the first year of life. Duration of exclusive breastfeeding was defined as the time during w…

MaleWritingIntelligenceLongitudinal StudieSettore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'EducazioneDevelopmental NeuroscienceChildDose-Response Relationship DrugSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaThimerosalPreservatives PharmaceuticalInfantTime and Motion StudieEducational StatuBreast FeedingItalyReadingDiphtheria-Tetanus-acellular Pertussis VaccinePediatrics Perinatology and Child HealthFemaleNeuropsychological TestNeurology (clinical)Cohort StudiePsychometricHumanWechsler Scale
researchProduct